From 1969 to 1982, 419 patients underwent single mitral valve replacement; of these, 48% had associated coronary artery disease (9% single vessel, 8% double vessel, 28% triple vessel, 3% left main). In 216 patients with no associated coronary disease, in 179 patients with coronary disease that was revascularized, and in 24 patients with coronary disease that was not revascularized, the 30 day mortalities were 4.2%, 13.9%, and 29.2% (p less than .05) after valve replacement. Actuarial survivals at 8 years were 68%, 44%, and 15%, respectively (p less than .01), with 1 to 165 months of follow-up (mean 52). After matching the three cohorts of patients in age, sex, left ventricular ejection fraction, and valve lesion, the presence of associated coronary artery disease decreased long-term survival and revascularization improved survival (p less than .05 for both). Incidental coronary disease in patients with rheumatic mitral valve disease had a significant negative influence on survival if left unbypassed (p less than .05); after revascularization and valve replacement, the 30 day mortality was 7.3% and the 8 year survival was 52%. Coronary disease etiologically related to ischemic mitral regurgitation identified a high-risk group of patients, with a 30 day mortality of 19.6% and an 8 year survival of 37% after the combined procedure. A multivariate logistic regression model was used to determine which preoperative and intraoperative variables predicted early and late outcome after combined mitral valve replacement and coronary revascularization. Predictors of early death were advanced age (greater than 60 years), New York Heart Association functional class (IV), an ischemic etiology of the mitral valve disease, and a depressed left ventricular ejection fraction (less than 55%). Predictors of late death were triple-vessel or left main coronary disease, increased left ventricular end-diastolic volume (greater than 120 ml/m2), and depressed left ventricular ejection fraction (less than 55%). These findings highlight the important etiologic and prognostic role of coronary artery disease in patients requiring mitral valve replacement.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pimobendan oral solution is bioequivalent to pimobendan chewable tablets in beagle dogs.
J Vet Intern Med
January 2025
Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, Germany.
Background: Myxomatous mitral valve disease (MMVD) is frequently diagnosed in small breed dogs. Pimobendan oral solution has been developed to improve dosing accuracy in small and toy breed dogs.
Hypothesis/objectives: Demonstrate bioequivalence of pimobendan oral solution with pimobendan chewable tablets using a pharmacokinetic and a pharmacodynamic study in healthy purpose bred dogs.
is rarely associated with neurological manifestations. This report describes a rare case of endocarditis complicated by a cerebral stroke caused by . We also briefly reviewed the neurological clinical spectrum of disease described in the literature.
View Article and Find Full Text PDFLingual artery thrombosis as a presentation of infective endocarditis in a pregnant patient: a case report.
Eur Heart J Case Rep
January 2025
Department of Cardiology, Clínica Alemana de Santiago, Avenida Manquehue Norte #1499, 7650568 Vitacura, Chile.
Background: Infective endocarditis during pregnancy is a rare condition that compromises the health of both the mother and the foetus, presenting high rates of morbidity and mortality. The clinical manifestations of this disease are varied, with embolic phenomena being a frequent presentation.
Case Summary: We report the case of a Hispanic 37-year-old patient, at 29 weeks of pregnancy, with no known cardiovascular history, who presented with 48 h of sudden mandibular and lingual pain.
Human infective endocarditis and septic shock caused by Streptococcus suis serotype 1.
BMC Infect Dis
January 2025
Wuming Hospital of Guangxi Medical University, Nanning, China.
Streptococcus suis(SS) infection is a zoonotic acute infectious disease, SS infective endocarditis is relatively rare, there is no case report of Streptococcus suis Serotype 1(SS1) causing mitral valve infection.The rapid progression of this patient's infection and the severe damage to the valve structure differ from the previous understanding of the relatively low virulence of SS1. Early diagnosis and selection of the correct antibiotic treatment according to the drug sensitivity is very important.
View Article and Find Full Text PDFCardiac papillary fibroelastoma involving the mitral valve: A case report.
Medicine (Baltimore)
January 2025
Ultrasound Medical Center, Second Hospital of Lanzhou University, Lanzhou, China.
Rationale: Cardiac papillary fibroelastoma (CPF) is a rare cardiac tumor that can lead to severe and potentially fatal complications such as stroke, myocardial infarction, and sudden cardiac death. The rarity of CPF makes it challenging for clinicians to diagnose and treat, highlighting the importance of timely and accurate diagnosis to prevent catastrophic outcomes. This case report aims to contribute to the clinical understanding of CPF involving the mitral valve (MV), providing insights into diagnosis and treatment strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!